Blood-brain barrier disruption for the treatment of malignant brain tumors

The National Program.

Nancy Doolittle, A. Petrillo, S. Bell, P. Cummings, S. Eriksen

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Chemotherapy delivery for the treatment of malignant brain tumors is markedly enhanced when given in conjunction with osmotic opening of the blood-brain barrier. Osmotic opening or disruption of the blood-brain barrier is achieved while the patient is under general anesthesia, by the infusion of mannitol into the internal carotid or vertebral artery circulation. The mannitol infusion is followed by administration of intraarterial chemotherapy. A National Blood-Brain Barrier Program now exists and includes six universities. Within the National Program over 4200 blood-brain barrier disruption procedures have been performed in over 400 patients. Patients with primary central nervous system (CNS) lymphoma, glioma, primitive neuroectodermal tumor (PNET), germ cell and metastatic cancer are eligible for treatment. Results in patients with primary CNS lymphoma, recently reported in the Cancer Journal, include the first example of a durable response in a primary brain tumor without loss of cognitive function and without use of radiotherapy. Results with PNET and germ cell tumors are also very encouraging. Advanced practice nurses coordinate the care of blood-brain barrier disruption patients. Care includes patients selection, education, close neurological observation, maintenance of fluid and electrolyte balance and managing effects of high-dose chemotherapy. Both acute and long-term medical and psychological follow-up are an essential component of the program, as well as patient and family support.

Original languageEnglish (US)
Pages (from-to)81-90
Number of pages10
JournalThe Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
Volume30
Issue number2
StatePublished - 1998

Fingerprint

Blood-Brain Barrier
Brain Neoplasms
Primitive Neuroectodermal Tumors
Water-Electrolyte Balance
Germ Cell and Embryonal Neoplasms
Mannitol
Drug Therapy
Lymphoma
Therapeutics
Central Nervous System
Vertebral Artery
Internal Carotid Artery
Glioma
General Anesthesia
Cognition
Patient Selection
Radiotherapy
Nurses
Maintenance
Observation

Cite this

Blood-brain barrier disruption for the treatment of malignant brain tumors : The National Program. / Doolittle, Nancy; Petrillo, A.; Bell, S.; Cummings, P.; Eriksen, S.

In: The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, Vol. 30, No. 2, 1998, p. 81-90.

Research output: Contribution to journalArticle

@article{e25d85b93dd34045a16c5f0a4ef6dba2,
title = "Blood-brain barrier disruption for the treatment of malignant brain tumors: The National Program.",
abstract = "Chemotherapy delivery for the treatment of malignant brain tumors is markedly enhanced when given in conjunction with osmotic opening of the blood-brain barrier. Osmotic opening or disruption of the blood-brain barrier is achieved while the patient is under general anesthesia, by the infusion of mannitol into the internal carotid or vertebral artery circulation. The mannitol infusion is followed by administration of intraarterial chemotherapy. A National Blood-Brain Barrier Program now exists and includes six universities. Within the National Program over 4200 blood-brain barrier disruption procedures have been performed in over 400 patients. Patients with primary central nervous system (CNS) lymphoma, glioma, primitive neuroectodermal tumor (PNET), germ cell and metastatic cancer are eligible for treatment. Results in patients with primary CNS lymphoma, recently reported in the Cancer Journal, include the first example of a durable response in a primary brain tumor without loss of cognitive function and without use of radiotherapy. Results with PNET and germ cell tumors are also very encouraging. Advanced practice nurses coordinate the care of blood-brain barrier disruption patients. Care includes patients selection, education, close neurological observation, maintenance of fluid and electrolyte balance and managing effects of high-dose chemotherapy. Both acute and long-term medical and psychological follow-up are an essential component of the program, as well as patient and family support.",
author = "Nancy Doolittle and A. Petrillo and S. Bell and P. Cummings and S. Eriksen",
year = "1998",
language = "English (US)",
volume = "30",
pages = "81--90",
journal = "Journal of Neuroscience Nursing",
issn = "0888-0395",
publisher = "American Association of Neuroscience Nurses",
number = "2",

}

TY - JOUR

T1 - Blood-brain barrier disruption for the treatment of malignant brain tumors

T2 - The National Program.

AU - Doolittle, Nancy

AU - Petrillo, A.

AU - Bell, S.

AU - Cummings, P.

AU - Eriksen, S.

PY - 1998

Y1 - 1998

N2 - Chemotherapy delivery for the treatment of malignant brain tumors is markedly enhanced when given in conjunction with osmotic opening of the blood-brain barrier. Osmotic opening or disruption of the blood-brain barrier is achieved while the patient is under general anesthesia, by the infusion of mannitol into the internal carotid or vertebral artery circulation. The mannitol infusion is followed by administration of intraarterial chemotherapy. A National Blood-Brain Barrier Program now exists and includes six universities. Within the National Program over 4200 blood-brain barrier disruption procedures have been performed in over 400 patients. Patients with primary central nervous system (CNS) lymphoma, glioma, primitive neuroectodermal tumor (PNET), germ cell and metastatic cancer are eligible for treatment. Results in patients with primary CNS lymphoma, recently reported in the Cancer Journal, include the first example of a durable response in a primary brain tumor without loss of cognitive function and without use of radiotherapy. Results with PNET and germ cell tumors are also very encouraging. Advanced practice nurses coordinate the care of blood-brain barrier disruption patients. Care includes patients selection, education, close neurological observation, maintenance of fluid and electrolyte balance and managing effects of high-dose chemotherapy. Both acute and long-term medical and psychological follow-up are an essential component of the program, as well as patient and family support.

AB - Chemotherapy delivery for the treatment of malignant brain tumors is markedly enhanced when given in conjunction with osmotic opening of the blood-brain barrier. Osmotic opening or disruption of the blood-brain barrier is achieved while the patient is under general anesthesia, by the infusion of mannitol into the internal carotid or vertebral artery circulation. The mannitol infusion is followed by administration of intraarterial chemotherapy. A National Blood-Brain Barrier Program now exists and includes six universities. Within the National Program over 4200 blood-brain barrier disruption procedures have been performed in over 400 patients. Patients with primary central nervous system (CNS) lymphoma, glioma, primitive neuroectodermal tumor (PNET), germ cell and metastatic cancer are eligible for treatment. Results in patients with primary CNS lymphoma, recently reported in the Cancer Journal, include the first example of a durable response in a primary brain tumor without loss of cognitive function and without use of radiotherapy. Results with PNET and germ cell tumors are also very encouraging. Advanced practice nurses coordinate the care of blood-brain barrier disruption patients. Care includes patients selection, education, close neurological observation, maintenance of fluid and electrolyte balance and managing effects of high-dose chemotherapy. Both acute and long-term medical and psychological follow-up are an essential component of the program, as well as patient and family support.

UR - http://www.scopus.com/inward/record.url?scp=0032037129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032037129&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 81

EP - 90

JO - Journal of Neuroscience Nursing

JF - Journal of Neuroscience Nursing

SN - 0888-0395

IS - 2

ER -